Charles River Laboratories has entered into definitive agreements to acquire Frontage Holdings Corporation’s bioanalysis and drug metabolism and pharmacokinetics businesses in Exton, Pennsylvania, for approximately $470 million in cash, with additional payments of up to $75 million contingent on future performance. The transaction could therefore reach approximately $545 million and will expand Charles River’s clinical bioanalysis capabilities.
The acquisition supports Charles River’s Pathway to Purpose strategy, which includes strengthening its scientific services and expanding support across the drug development lifecycle.
Frontage’s acquired operations provide bioanalytical testing, biomarker analysis, and drug metabolism and pharmacokinetics services.
These capabilities are used by pharmaceutical and biotechnology companies evaluating investigational treatments.
The transaction encompasses two facilities in Exton, Pennsylvania, spanning approximately 150,000 square feet.
The sites employ approximately 340 people and include a laboratory certified under the Clinical Laboratory Improvement Amendments.
Frontage’s operations support the analysis of large and small molecules, with a particular emphasis on testing conducted during clinical development.
The acquisition will complement Charles River’s established capabilities in preclinical bioanalysis.
Currently, approximately 15% of Charles River’s bioanalysis revenue comes from clinical-stage testing.
The addition of Frontage will expand that portion of the business, allowing the company to support customers as drug candidates progress from early research into clinical trials.
Charles River believes this continuity can improve client relationships by allowing customers to work with a more integrated scientific services provider.
The acquisition also strengthens its capabilities involving biologics and complex therapeutic modalities.
These products can require specialized testing methods and advanced analytical techniques throughout development.
Biologics and complex modalities currently represent approximately 75% of Charles River’s bioanalysis revenue.
The company expects demand for specialized testing to increase as these therapies represent a growing share of pharmaceutical development programs.
According to market estimates cited by Charles River, the global bioanalysis sector could expand from approximately $6 billion in 2026 to between $8 billion and $9 billion by 2031.
That represents projected annual growth of approximately 6% to 8%.
The company expects stronger growth in clinical-stage testing and complex therapeutic modalities.
The acquired Frontage operations represented approximately 40% of Frontage’s $256.7 million in total revenue during 2025.
Charles River expects the acquired businesses to grow at a rate consistent with the projected broader bioanalysis market over the next five years.
The transaction is expected to be neutral to Charles River’s non-GAAP earnings per share during 2027 and accretive thereafter.
Charles River plans to finance the acquisition using available cash and its credit facility.
The transaction involves a broader restructuring of Frontage Holdings, which is listed on the Hong Kong Stock Exchange.
Charles River is participating in an acquisition consortium alongside Hongkong Tigermed, a subsidiary of Hangzhou Tigermed Consulting, and Frontage Chairman Dr. Song Li.
The consortium intends to privatize Frontage through a court-sanctioned scheme of arrangement.
Following privatization, the businesses will be separated into different subsidiaries.
Charles River will retain the Exton-based bioanalysis and drug metabolism and pharmacokinetics operations.
Frontage’s other businesses will be transferred to Tigermed and Dr. Song Li or their affiliates.
The acquisition remains subject to shareholder, regulatory, and court approvals.
Completion is expected during the first half of 2027.
J.P. Morgan and CICC are serving as joint financial advisors to the acquisition consortium.
The proposed transaction will increase Charles River’s clinical testing capacity and expand its role in supporting pharmaceutical and biotechnology customers throughout drug development.
KEY QUOTES:
“The planned acquisition accelerates our strategy to expand our bioanalysis capabilities and enhance our offering in an attractive, high-growth market. As biologics and increasingly complex modalities become a larger part of development pipelines, clients are seeking scientific partners that can support programs from early development through the clinic. By adding Frontage’s clinical bioanalysis expertise, talented scientific team, and strong client relationships, we will be better positioned to meet those evolving needs.”
“This acquisition will advance our Pathway to Purpose strategy by expanding our presence in clinical bioanalysis, strengthening our scientific leadership, and enhancing our ability to serve clients across the drug development lifecycle. Our combined bioanalysis and DMPK offering will provide a more integrated solution that accelerates development timelines and improves continuity from preclinical through clinical testing. The transaction is expected to enhance our growth profile and support long-term value creation for clients and shareholders. We look forward to welcoming Frontage’s talented bioanalysis and DMPK team to the Charles River family.”
Birgit Girshick, CEO Of Charles River Laboratories
